🇺🇸 FDA
Patent

US 9068003

Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies

granted A61PA61P1/00A61P1/04

Quick answer

US patent 9068003 (Antibodies that bind to TL1A and methods of treating inflammatory or autoimmune disease comprising administering such antibodies) held by The United States of America as Represented by the Secretary, Dept. of Health and Human Services expires Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America as Represented by the Secretary, Dept. of Health and Human Services
Grant date
Tue Jun 30 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 25 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
13
CPC classes
A61P, A61P1/00, A61P1/04, A61P11/06, A61P19/02